Medpace Holdings, Inc.

MEDP Healthcare Diagnostics & Research

Medpace Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 20.0% from fiscal 2024.

Revenue
+8.50%
EPS
+24.6%
Free cash flow
−16.6%

Quarter to September 2026, against a year earlier

649.05 14.07 +2.22%
Market cap
$17.8B
P/E
34.6×
Fwd P/E
35.8×
Dividend yield
—
F-score
8/9
Altman Z
8.04
Beneish M
−2.92
Dividend safety
n/a

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Older periods Dec '25 Mar '26 Jun '26 Sep '26
Revenue

+8 more quarters

708.45 706.60 707.33 716.00
Revenue Growth
32.03% 26.50% 17.24% 8.50%
Gross Profit
526.30 508.33 504.78 511.15
Operating Income
153.27 141.50 146.82 165.54
EBT
156.83 147.59 151.66 170.91
Income after Tax
135.13 123.87 121.36 137.46
Net Income Common
135.13 123.87 121.36 137.46
EPS (Diluted)
4.67 4.28 4.25 4.84
Shares (Diluted, Weighted)
29.53 28.96 28.55 28.37
Gross Margin
74.29% 71.94% 71.36% 71.39%
EBIT Margin
21.63% 20.03% 20.76% 23.12%
Net Profit Margin
19.07% 17.53% 17.16% 19.20%
EBITDA
160.40 148.41 153.53 172.12
EBIT
153.27 141.50 146.82 165.54

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 2 Nov 2026